Status:
COMPLETED
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Nasopharyngeal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This single arm study will assess the efficacy and safety of Xeloda + oxaliplatin when given as first line treatment for patients with metastatic nasopharyngeal cancer. Patients will receive Xeloda (1...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- history of nasopharyngeal cancer and distant metastases;
- no previous chemotherapy in past 6 months;
- recovery from previous radiotherapy;
- ability to swallow and retain oral medication.
Exclusion
- previous cytotoxic chemotherapy;
- radiotherapy within 4 weeks of treatment start;
- history of another malignancy within the last 5 years;
- clinically significant cardiac disease.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00439426
Start Date
April 1 2007
End Date
September 1 2009
Last Update
November 2 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Agadir, Morocco, 80000
2
Casablanca, Morocco, 20502
3
Marrakesh, Morocco, 40000
4
Rabat, Morocco, 10000